Edition:
United Kingdom

BioLife Solutions Inc (BLFS.OQ)

BLFS.OQ on NASDAQ Stock Exchange Capital Market

8.91USD
18 May 2018
Change (% chg)

$-0.15 (-1.66%)
Prev Close
$9.06
Open
$9.05
Day's High
$9.21
Day's Low
$8.83
Volume
26,849
Avg. Vol
20,907
52-wk High
$9.21
52-wk Low
$2.13

Chart for

About

BioLife Solutions, Inc. (BioLife) is engaged in the developing, manufacturing and marketing a portfolio of biopreservation tools and services for cells, tissues and organs, including clinical grade cell and tissue hypothermic storage and cryopreservation freeze media and a related cloud hosted biologistics cold chain management... (more)

Overall

Beta: 0.27
Market Cap(Mil.): $76.06
Shares Outstanding(Mil.): 13.23
Dividend: --
Yield (%): --

Financials

  BLFS.OQ Industry Sector
P/E (TTM): -- 30.95 32.75
EPS (TTM): -0.46 -- --
ROI: -86.26 14.84 14.38
ROE: -86.94 16.34 16.07

BRIEF-Casdin Capital To Become Shareholder In Biolife Solutions

* CASDIN CAPITAL LLC, ENTERED INTO AN AGREEMENT TO PURCHASE 1,000,000 BIOLIFE SOLUTIONS SHARES IN PRIVATE DEAL Source text for Eikon: Further company coverage:

09 Apr 2018

BRIEF-BioLife Solutions Announces Preliminary Q1 Revenue Of $3.8 Mln, Up 61 Pct

* FOR 2018 BIOPRESERVATION MEDIA REVENUE EXPECTED TO RANGE BETWEEN $14.5 MILLION TO $15.5 MILLION

02 Apr 2018

BRIEF-BioLife Solutions Q4 Loss Per Share $0.05

* BIOLIFE SOLUTIONS ANNOUNCES FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS

08 Mar 2018

BRIEF-Biolife Solutions Executes OEM Agreement With MilliporeSigma

* BIOLIFE SOLUTIONS EXECUTES OEM AGREEMENT WITH MILLIPORESIGMA Source text for Eikon: Further company coverage:

13 Feb 2018

BRIEF-Biolife Solutions Says Co And Savsu Technologies Amended Their Arrangement With Respect To JV

* BIOLIFE SOLUTIONS SAYS ON JAN 22 CO AND SAVSU TECHNOLOGIES AMENDED THEIR ARRANGEMENT WITH RESPECT TO THEIR JV, BIOLOGISTEX- SEC FILING

26 Jan 2018

BRIEF-Biolife Solutions Executes Supply Agreement With Iovance Biotherapeutics

* BIOLIFE SOLUTIONS EXECUTES SUPPLY AGREEMENT WITH IOVANCE BIOTHERAPEUTICS

13 Dec 2017

BRIEF-Biolife Solutions Executes Additional Long-Term Supply Agreement With Leading T Cell Therapy Customer

* BIOLIFE SOLUTIONS EXECUTES ADDITIONAL LONG-TERM SUPPLY AGREEMENT WITH LEADING T CELL THERAPY CUSTOMER Source text for Eikon: Further company coverage:

29 Nov 2017

Competitors

Earnings vs. Estimates